India’s NPPA has approved capping trade margins on non-scheduled cancer drugs at 30% of MRP, targeting markups that averaged about 170% and reached 700% in some cases. What it means for patients and how will the cap work? ....
The NPPA's decision aims to make cancer treatment more affordable by curbing excessive trade margins, with patients expected to save around Rs 2,500 crore annually ....
Under the order, the maximum retail price (MRP) of these medicines cannot exceed the price fixed by the NPPA... The NPPA said pharmaceutical companies cannot charge more than the notified price.